{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:12:45Z","timestamp":1696331565080},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T00:00:00Z","timestamp":1377216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00280-013-2253-3","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T13:07:15Z","timestamp":1377176835000},"page":"777-788","source":"Crossref","is-referenced-by-count":6,"title":["Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma"],"prefix":"10.1007","volume":"72","author":[{"given":"Sheng-hua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-guang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,23]]},"reference":[{"issue":"1","key":"2253_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63(1):11\u201330","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"6","key":"2253_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.breast.2005.10.001","volume":"14","author":"P Boyle","year":"2005","unstructured":"Boyle P (2005) Breast cancer control: signs of progress, but more work required. Breast 14(6):429\u2013438","journal-title":"Breast"},{"issue":"4","key":"2253_CR3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1054\/bjoc.2001.1969","volume":"85","author":"R Demicheli","year":"2001","unstructured":"Demicheli R, Valagussa P, Bonadonna G (2001) Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 85(4):490\u2013492","journal-title":"Br J Cancer"},{"issue":"4","key":"2253_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archsurg.1995.01430040049007","volume":"130","author":"E Hansen","year":"1995","unstructured":"Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K (1995) Tumor cells in blood shed from the surgical field. Arch Surg 130(4):387\u2013393","journal-title":"Arch Surg"},{"issue":"11","key":"2253_CR5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.7164\/antibiotics.41.1575","volume":"41","author":"JL Hu","year":"1988","unstructured":"Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y, Yamada Y, Marunaka T (1988) A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot 41(11):1575\u20131579 Tokyo","journal-title":"J Antibiot"},{"issue":"2","key":"2253_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/187152008783497055","volume":"8","author":"RG Shao","year":"2008","unstructured":"Shao RG, Zhen YS (2008) Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem 8(2):123\u2013131","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"2253_CR7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1874467210801010050","volume":"1","author":"RG Shao","year":"2008","unstructured":"Shao RG (2008) Pharmacology and therapeutic applications of enediyne antitumor antibiotics. Curr Mol Pharmacol 1(1):50\u201360","journal-title":"Curr Mol Pharmacol"},{"issue":"5","key":"2253_CR8","first-page":"336","volume":"30","author":"RG Shao","year":"1995","unstructured":"Shao RG, Zhen YS (1995) Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity. Yao Xue Xue Bao 30(5):336\u2013342","journal-title":"Yao Xue Xue Bao"},{"issue":"23","key":"2253_CR9","doi-asserted-by":"crossref","first-page":"20549","DOI":"10.1074\/jbc.M109897200","volume":"277","author":"J Dziegielewski","year":"2002","unstructured":"Dziegielewski J, Beerman TA (2002) Cellular responses to the DNA strand-scission enediyne C-1027 can be independent of ATM, ATR, and DNA-PK kinases. J Biol Chem 277(23):20549\u201320554","journal-title":"J Biol Chem"},{"issue":"2","key":"2253_CR10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-08-2753","volume":"69","author":"TA Beerman","year":"2009","unstructured":"Beerman TA, Gawron LS, Shin S, Shen B, McHugh MM (2009) C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells. Cancer Res 69(2):593\u2013598","journal-title":"Cancer Res"},{"issue":"6","key":"2253_CR11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4161\/cbt.6.6.4193","volume":"6","author":"L Chen","year":"2007","unstructured":"Chen L, Jiang J, Cheng C, Yang A, He Q, Li D, Wang Z (2007) P53 dependent and independent apoptosis induced by lidamycin in human colorectal cancer cells. Cancer Biol Ther 6(6):965\u2013973","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2253_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/CAD.0b013e328318292c","volume":"20","author":"H Liu","year":"2009","unstructured":"Liu H, Li L, Li XQ, Liu XJ, Zhen YS (2009) Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. Anticancer Drugs 20(1):41\u201349","journal-title":"Anticancer Drugs"},{"issue":"4","key":"2253_CR13","first-page":"456","volume":"45","author":"LL Ding","year":"2010","unstructured":"Ding LL, Liu M, Zhang SH, Zhao XZ, Wu N, Chen L, Wang GJ, Lin XK (2010) Lidamycin inhibits angiogenesis of zebrafish embryo via down-regulation of VEGF. Yao Xue Xue Bao 45(4):456\u2013461","journal-title":"Yao Xue Xue Bao"},{"issue":"2","key":"2253_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1634\/theoncologist.6-2-133","volume":"6","author":"FJ Esteva","year":"2001","unstructured":"Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6(2):133\u2013146","journal-title":"Oncologist"},{"issue":"4","key":"2253_CR15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0014-2964(80)90221-2","volume":"16","author":"W Bollag","year":"1980","unstructured":"Bollag W, Hartmann HR (1980) Tumor inhibitory effects of a new fluorouracil derivative: 5\u2032-deoxy-5-fluorouridine. Eur J Cancer 16(4):427\u2013432","journal-title":"Eur J Cancer"},{"issue":"1","key":"2253_CR16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27(1):23\u201344","journal-title":"Clin Ther"},{"key":"2253_CR17","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/S0021-9258(18)93897-4","volume":"239","author":"M Zimmerman","year":"1964","unstructured":"Zimmerman M (1964) Deoxyribosyl Transfer. Ii. Nucleoside:pyrimidine deoxyribosyltransferase activity of three partially purified thymidine phosphorylases. J Biol Chem 239:2622\u20132627","journal-title":"J Biol Chem"},{"issue":"10","key":"2253_CR18","first-page":"2948","volume":"5","author":"N Sawada","year":"1999","unstructured":"Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H (1999) X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5(10):2948\u20132953","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2253_CR19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ijc.1212","volume":"92","author":"T Morita","year":"2001","unstructured":"Morita T, Matsuzaki A, Tokue A (2001) Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 92(3):451\u2013456","journal-title":"Int J Cancer"},{"issue":"4","key":"2253_CR20","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res 4(4):1013\u20131019","journal-title":"Clin Cancer Res"},{"key":"2253_CR21","first-page":"923","volume":"1","author":"J Ciccolini","year":"2002","unstructured":"Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, Cuq P, Romain S, Martin PM, Aubert C (2002) Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 1:923\u2013927","journal-title":"Mol Cancer Ther"},{"key":"2253_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1179\/joc.2010.22.2.129","volume":"22","author":"M Chefrour","year":"2010","unstructured":"Chefrour M, Fischel JL, Formento P, Giacometti S, Ferri-Dessens RM, Marouani H, Francoual M, Renee N, Mercier C, Milano G, Ciccolini J (2010) Erlotinib in combination with capecitabine (5\u2032dFUR) in resistant pancreatic cancer cell lines. J Chemother 22:129\u2013133","journal-title":"J Chemother"},{"key":"2253_CR23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1472-8206.2011.00945.x","volume":"26","author":"M Chefrour","year":"2012","unstructured":"Chefrour M, Milano G, Formento P, Giacometti S, Denden A, Ren\u00e9e N, Iliadis A, Fischel J-L, Ciccolini J (2012) Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundam Clin Pharmacol 26:530\u2013537","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"2253_CR24","first-page":"1079","volume":"7","author":"K Fujimoto-Ouchi","year":"2001","unstructured":"Fujimoto-Ouchi K, Tanaka Y, Tominaga T (2001) Schedule dependency of antitumor activity in combination therapy with capecitabine\/5\u2032-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7(4):1079\u20131086","journal-title":"Clin Cancer Res"},{"key":"2253_CR25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00280-012-1827-9","volume":"69","author":"JH Gong","year":"2012","unstructured":"Gong JH, Liu XJ, Li Y, Zhen YS (2012) Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemoth Pharm 69:1323\u20131332","journal-title":"Cancer Chemoth Pharm"},{"issue":"51","key":"2253_CR26","doi-asserted-by":"crossref","first-page":"35598","DOI":"10.1074\/jbc.M802253200","volume":"283","author":"K Ren","year":"2008","unstructured":"Ren K, Jin H, Bian C, He H, Liu X, Zhang S, Wang Y, Shao RG (2008) MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)\/focal adhesion kinase (FAK)\/Akt signaling pathway. J Biol Chem 283(51):35598\u201335605","journal-title":"J Biol Chem"},{"issue":"6","key":"2253_CR27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","volume":"40","author":"MC Bibby","year":"2004","unstructured":"Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40(6):852\u2013857","journal-title":"Eur J Cancer"},{"key":"2253_CR28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02789239","volume":"24\u201325","author":"SA Eccles","year":"1994","unstructured":"Eccles SA, Box G, Court W, Sandle J, Dean CJ (1994) Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys 24\u201325:279\u2013291","journal-title":"Cell Biophys"},{"issue":"4","key":"2253_CR29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1006326203858","volume":"17","author":"RM Hoffman","year":"1999","unstructured":"Hoffman RM (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17(4):343\u2013359","journal-title":"Invest New Drugs"},{"issue":"3","key":"2253_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11154-007-9041-5","volume":"8","author":"AE Vernon","year":"2007","unstructured":"Vernon AE, Bakewell SJ, Chodosh LA (2007) Deciphering the molecular basis of breast cancer metastasis with mouse models. Rev Endocr Metab Disord 8(3):199\u2013213","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2253_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.1.3.1","volume":"3","author":"BL Eckhardt","year":"2005","unstructured":"Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3(1):1\u201313","journal-title":"Mol Cancer Res"},{"issue":"12 Suppl","key":"2253_CR32","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","volume":"88","author":"T Yoneda","year":"2000","unstructured":"Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88(12 Suppl):2979\u20132988","journal-title":"Cancer"},{"issue":"6","key":"2253_CR33","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399\u20131405","journal-title":"Cancer Res"},{"issue":"2","key":"2253_CR34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1006689719505","volume":"17","author":"M Lelekakis","year":"1999","unstructured":"Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17(2):163\u2013170","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"2253_CR35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485\u2013493","journal-title":"J Clin Oncol"},{"issue":"8","key":"2253_CR36","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274\u20131281","journal-title":"Eur J Cancer"},{"issue":"4","key":"2253_CR37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Schuller","year":"2000","unstructured":"Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291\u2013297","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2253_CR38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/15257770802143988","volume":"27","author":"IV Bijnsdorp","year":"2008","unstructured":"Bijnsdorp IV, de Bruin M, Laan AC, Fukushima M, Peters GJ (2008) The role of platelet-derived endothelial cell growth factor\/thymidine phosphorylase in tumor behavior. Nucleosides, Nucleotides Nucleic Acids 27(6):681\u2013691","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"issue":"1","key":"2253_CR39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1124\/jpet.111.179663","volume":"338","author":"JC Ko","year":"2011","unstructured":"Ko JC, Tsai MS, Chiu YF, Weng SH, Kuo YH, Lin YW (2011) Up-regulation of extracellular signal-regulated kinase 1\/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells. J Pharmacol Exp Ther 338(1):184\u2013194","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2253_CR40","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bcp.2007.05.008","volume":"74","author":"S Liekens","year":"2007","unstructured":"Liekens S, Bronckaers A, Perez\u2013Perez MJ, Balzarini J (2007) Targeting platelet-derived endothelial cell growth factor\/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 74(11):1555\u20131567","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"2253_CR41","first-page":"1445","volume":"17","author":"J Chen","year":"2007","unstructured":"Chen J, Ouyang ZG, Zhang SH, Zhen YS (2007) Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol Rep 17(6):1445\u20131451","journal-title":"Oncol Rep"},{"issue":"26","key":"2253_CR42","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v11.i26.3980","volume":"11","author":"YH Huang","year":"2005","unstructured":"Huang YH, Shang BY, Zhen YS (2005) Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol 11(26):3980\u20133984","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2253_CR43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00735915","volume":"32","author":"H Eda","year":"1993","unstructured":"Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H (1993) Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5\u2032-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32(5):333\u2013338","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2253_CR44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.1993.tb02876.x","volume":"84","author":"H Eda","year":"1993","unstructured":"Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, Tanaka Y, Ishitsuka H (1993) Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5\u2032-deoxy-5-fluorouridine. Jpn J Cancer Res 84(3):341\u2013347","journal-title":"Jpn J Cancer Res"},{"issue":"2\u20133","key":"2253_CR45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0959-8049(05)80055-3","volume":"28","author":"HT Tevaearai","year":"1992","unstructured":"Tevaearai HT, Laurent PL, Suardet L, Eliason JF, Givel JC, Odartchenko N (1992) Interactions of interferon-alpha 2a with 5\u2032-deoxy-5-fluorouridine in colorectal cancer cells in vitro. Eur J Cancer 28(2\u20133):368\u2013372","journal-title":"Eur J Cancer"},{"issue":"55","key":"2253_CR46","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1038\/sj.onc.1206030","volume":"21","author":"GH Zhu","year":"2002","unstructured":"Zhu GH, Lenzi M, Schwartz EL (2002) The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells. Oncogene 21(55):8477\u20138485","journal-title":"Oncogene"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2253-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2253-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:56:20Z","timestamp":1688432180000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2253-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,23]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2253-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,23]]}}}